1. Scrip
  2. >>Focus On Asia

Shanghai MicroPort Gets China Approval For Targeted Drug-eluting Stent

Shanghai MicroPort Medical announced that its Firehawk Rapamycin-eluting coronary stent was approved by China FDA.

Shanghai MicroPort Medical announced that its Firehawk Rapamycin-eluting coronary stent was approved by China FDA. The product is the only targeted drug-eluting stent system in the world, the company said. Targeted unidirectional eluting technology with fully biodegradable polymers generates precisely controlled drug-release kinetics. The applied targeted eluting technology allows Firehawk to achieve the same clinical efficacy as other traditional DES with only one-third the dosage, the company said (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.